{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:14:12Z","timestamp":1791486852312,"version":"4.3.4"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.biopha.2025.117878","type":"journal-article","created":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T19:40:17Z","timestamp":1738352417000},"page":"117878","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Enhancing T cell cytotoxicity in multiple myeloma with bispecific \u03b1PD-L1\u202f\u00d7\u202f\u03b1CD3 T cell engager-armed T cells and low-dose bortezomib therapy"],"prefix":"10.1016","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1951-9948","authenticated-orcid":false,"given":"Nunghathai","family":"Sawasdee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3045-9539","authenticated-orcid":false,"given":"Chutamas","family":"Thepmalee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutita","family":"Junking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3124-5206","authenticated-orcid":false,"given":"Seiji","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3634-1881","authenticated-orcid":false,"given":"Aussara","family":"Panya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pa-thai","family":"Yenchitsomanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.117878_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1243997","article-title":"Molecular and immunological mechanisms of clonal evolution in multiple myeloma","volume":"14","author":"Forster","year":"2023","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2025.117878_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.sjbs.2023.103920","article-title":"An overview of multiple myeloma: a monoclonal plasma cell malignancy\u2019s diagnosis, management, and treatment modalities","volume":"31","author":"Abduh","year":"2024","journal-title":"Saudi J. Biol. Sci."},{"key":"10.1016\/j.biopha.2025.117878_bib3","article-title":"Multiple myeloma: an overview of management","volume":"13","author":"Bird","year":"2019","journal-title":"Palliat. Care Soc. Pract."},{"issue":"10","key":"10.1016\/j.biopha.2025.117878_bib4","first-page":"684","article-title":"Multiple myeloma: from diagnosis to treatment","volume":"42","author":"Eslick","year":"2013","journal-title":"Aust. Fam. Physician"},{"issue":"9","key":"10.1016\/j.biopha.2025.117878_bib5","doi-asserted-by":"crossref","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","article-title":"The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends","volume":"9","author":"Huang","year":"2022","journal-title":"Lancet Haematol."},{"issue":"6","key":"10.1016\/j.biopha.2025.117878_bib6","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41408-022-00695-5","article-title":"Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee","volume":"12","author":"Kumar","year":"2022","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.biopha.2025.117878_bib7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41420-024-01818-6","article-title":"Targeted immunotherapy: harnessing the immune system to battle multiple myeloma","volume":"10","author":"Xu","year":"2024","journal-title":"Cell Death Discov."},{"issue":"5","key":"10.1016\/j.biopha.2025.117878_bib8","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s10238-022-00878-1","article-title":"Immune checkpoint inhibition improves antimyeloma activity of bortezomib and STING agonist combination in Vk*MYC preclinical model","volume":"23","author":"Sokolowska","year":"2023","journal-title":"Clin. Exp. Med"},{"issue":"1","key":"10.1016\/j.biopha.2025.117878_bib9","doi-asserted-by":"crossref","first-page":"6154","DOI":"10.1038\/s41598-022-09964-6","article-title":"Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells","volume":"12","author":"Wathikthinnakon","year":"2022","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2025.117878_bib10","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.3390\/curroncol30020179","article-title":"Relapsed\/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse","volume":"30","author":"Bhatt","year":"2023","journal-title":"Curr. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2025.117878_bib11","doi-asserted-by":"crossref","DOI":"10.1158\/2643-3230.BCD-21-0059","article-title":"Bortezomib Induces Immunogenic Cell Death in Multiple Myeloma","volume":"2","author":"Zitvogel","year":"2021","journal-title":"Blood Cancer Discov."},{"issue":"14","key":"10.1016\/j.biopha.2025.117878_bib12","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.biopha.2025.117878_bib13","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2012.213","article-title":"Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma","volume":"27","author":"Tamura","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.biopha.2025.117878_bib14","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-\u03b3 and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway","volume":"110","author":"Liu","year":"2007","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.biopha.2025.117878_bib15","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/s41379-022-01139-y","article-title":"The effect of neoadjuvant therapy on PD-L1 expression and CD8+lymphocyte density in non-small cell lung cancer","volume":"35","author":"Zens","year":"2022","journal-title":"Mod. Pathol."},{"issue":"10","key":"10.1016\/j.biopha.2025.117878_bib16","first-page":"5713","article-title":"Positive Conversion of PD-L1 Expression After Treatments with Chemotherapy and Nivolumab","volume":"37","author":"Haratake","year":"2017","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.biopha.2025.117878_bib17","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.tranon.2018.08.005","article-title":"Chemotherapeutic Treatments Increase PD-L1 Expression in Esophageal Squamous Cell Carcinoma through EGFR\/ERK Activation","volume":"11","author":"Ng","year":"2018","journal-title":"Transl. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.117878_bib18","article-title":"TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma","volume":"3","author":"Leduc","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.biopha.2025.117878_bib19","first-page":"4417","article-title":"Eosinophils Upregulate PD-L1 and PD-L2 Expression to Enhance the Immunosuppressive Microenvironment in Multiple Myeloma","volume":"130","author":"Driscoll","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.biopha.2025.117878_bib20","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s00262-017-2005-z","article-title":"KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma","volume":"66","author":"Chen","year":"2017","journal-title":"Cancer Immunol., Immunother."},{"issue":"3","key":"10.1016\/j.biopha.2025.117878_bib21","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/2326-6066.CIR-14-0207","article-title":"Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies","volume":"3","author":"Johnson","year":"2015","journal-title":"Cancer Immunol. Res"},{"issue":"1","key":"10.1016\/j.biopha.2025.117878_bib22","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40364-021-00294-9","article-title":"The landscape of bispecific T cell engager in cancer treatment","volume":"9","author":"Zhou","year":"2021","journal-title":"Biomark. Res."},{"issue":"3","key":"10.1016\/j.biopha.2025.117878_bib23","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1080\/21645515.2018.1540828","article-title":"Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies","volume":"15","author":"Burt","year":"2019","journal-title":"Hum. Vaccin Immunother."},{"issue":"3","key":"10.1016\/j.biopha.2025.117878_bib24","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1177\/2040620716640422","article-title":"The role of blinatumomab in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"7","author":"Benjamin","year":"2016","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.biopha.2025.117878_bib25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2147\/ITT.S240886","article-title":"Immunotherapeutic and Targeted Approaches in Multiple Myeloma","volume":"9","author":"Nadeem","year":"2020","journal-title":"Immunotargets Ther."},{"issue":"3","key":"10.1016\/j.biopha.2025.117878_bib26","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1158\/1535-7163.MCT-04-0260","article-title":"The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim","volume":"4","author":"Nikrad","year":"2005","journal-title":"Mol. Cancer Ther."},{"issue":"12","key":"10.1016\/j.biopha.2025.117878_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168193","article-title":"The Proteasome Inhibitor Bortezomib Affects Chondrosarcoma Cells via the Mitochondria-Caspase Dependent Pathway and Enhances Death Receptor Expression and Autophagy","volume":"11","author":"Lohberger","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.biopha.2025.117878_bib28","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13045-018-0589-1","article-title":"Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1\/PD-L1 pathway","volume":"11","author":"Tremblay-LeMay","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"19","key":"10.1016\/j.biopha.2025.117878_bib29","doi-asserted-by":"crossref","first-page":"16639","DOI":"10.1074\/jbc.M200360200","article-title":"NF-kappa B as a therapeutic target in multiple myeloma","volume":"277","author":"Hideshima","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.biopha.2025.117878_bib30","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/blood-2009-01-199604","article-title":"Bortezomib induces canonical nuclear factor-\u03baB activation in multiple myeloma cells","volume":"114","author":"Hideshima","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.biopha.2025.117878_bib31","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2025.117878_bib32","series-title":"Resistance to Proteasome Inhibitors in Cancer: Molecular Mechanisms and Strategies to Overcome Resistance","first-page":"1","article-title":"Proteasome Inhibitors and Lessons Learned from Their Mechanisms of Action and Resistance in Human Cancer","author":"Schmitt","year":"2014"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225000721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225000721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T23:43:48Z","timestamp":1741045428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225000721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":32,"alternative-id":["S0753332225000721"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.117878","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing T cell cytotoxicity in multiple myeloma with bispecific \u03b1PD-L1\u202f\u00d7\u202f\u03b1CD3 T cell engager-armed T cells and low-dose bortezomib therapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.117878","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117878"}}